ABSTRACT
INTRODUCTION
A cataract is an opacity or cloudiness of the crystalline lens which may prevent a clear image from forming in the cornea, and is the leading cause of blindness worldwide. 1 Age-related cataracts are responsible for 48% of world blindness, or about 18 million people. 2 In the United States, about 300,000-400,000 new visually-disabling cataracts occur annually. monofocal IOLs. 4 The aim of these multifocal
IOLs, therefore, is to allow patients to achieve spectacle independence. These lenses, however,
are not without limitations, with some patients reporting problems with halos, glare, and loss of contrast sensitivity. 5, 6 The OptiVis™ Multifocal IOL (Aaren Scientific, 
METHODS
This study was a 6 month, open-label, nonrandomized clinical trial of 121 enrolled eyes expected to undergo bilateral implantation with the OptiVis multifocal IOL, with the second surgery at least 1 week, and no more than 4 weeks, after the first surgery. For each subject, the decision for which eye to operate on first was at the discretion of the physician.
After each surgery, each subject was examined 
RESULTS
Eighty-eight eyes of 44 patients completed the 6-month clinical trials at two clinical sites; in France and in Italy.
Demographics
The mean age of implanted patients (121 eyes) was 70.43 ± 6.33 years.
Baseline Acuity
The mean preoperative BCDVA (121 eyes) was 20/50 and the mean preoperative UCDVA (121 eyes) was 20/80. 
Monocular Visual Acuity

BCDVA
Patient Satisfaction
Overall, patients were very satisfied with the visual outcomes after undergoing implantation were completely satisfied with the postoperative vision and 50% were mostly satisfied.
Adverse Events
The overall incidence of adverse events was mildto-moderate halos at 36% (n=30/84 eyes), with 22 reported as mild and eight reported as severe. reduction in visual quality due to glare and halos.
Those side effects can limit visual function and reduce patient quality of life. 7 In some models, the incidence of glare and halo have been reported to range from 6% to 40% for glare, and from 11% to 44% for halo. [8] [9] [10] [11] Although, in recent years, the newest multifocal IOLs are typically associated with lower incidence of these phenomenon, [12] [13] a recent study of 2500 patients reported that 6.1% of patients treated with Tecnis™ (Abbott Medical Optics Inc., Santa Ana, CA, USA) multifocal IOLs experience glare and 2.1% experience halo. 14 In the present study, the incidence of glare and halo was considerably lower than many previous reports, with a combined incidence of only 6.7%, and no severe incidence reported.
Patients in the present study also did not appear to have a reduction in contrast sensitivity after implantation of the OptiVis Multifocal IOL.
These results were comparable to a previously published report by Hohberger and associates who evaluated contrast sensitivity in normal subjects in an age cohort similar to the patients in this study (>60 years of age). 15 The finding that the majority of patients had optimal visual outcomes, not only at distance 
